Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Intea Fastigheter in connection with a directed share issue of approximately SEK 500 million
Mandate

Vinge has advised Intea Fastigheter in connection with a directed share issue of approximately SEK 500 million

December 01, 2025 M&A General Corporate

Vinge has advised the property company Intea Fastigheter AB (publ) in connection with a directed share issue of shares of series D through which the company raises proceeds of approximately SEK 500 million before transaction costs. A part of the share issue is subject to subsequent approval at an extraordinary general meeting.

The company intends to use the proceeds to pursue business opportunities in the current market and at the same time maintain a flexible and balanced capital structure. Intea Fastigheter’s shares of series B and D are listed on Nasdaq Stockholm, Mid Cap.

Vinge’s team consisted of Linnéa Dolk, Maximilian Bengtsson and Hannah Mark.

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026